Clinical Trials · NCT06047548
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 441
- Start date
- Sep 2023
- Locations
- 20 sites, United States
- Primary endpoint
- Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period